HANGZHOU, China /PRNewswire/ -- Lung cancer is a major and growing global epidemic, according to Billy W. Loo, Jr., M.D., assistant professor of radiation oncology at Stanford University in Palo Alto, California. Dr. Loo was one of three preeminent experts who made presentations at a special symposium for Chinese radiation oncology professionals sponsored by Varian and held in connection with the 2nd Chinese Society of Therapeutic Radiology and Oncology and Sino-American Network for Therapeutic Radiology and Oncology (CSTRO/SANTRO ) Joint Meeting in Hangzhou, China earlier this month.

"Early stage cases, and especially those patients who are unfit for surgery, can be effectively treated using stereotactic ablative radiotherapy (SABR), a very fast, image-guided, arc-based approach," said Dr. Loo. "Varian's technologies for this type of treatment-the Trilogy and TrueBeam systems for image-guided radiotherapy-are an attractive way to deliver SABR."

SABR, which is also referred to as stereotactic body radiotherapy (SBRT), involves the use of highly focused radiation concentrated on small tumors that have been discovered early, so it depends on early detection, said Dr. Loo, who uses Varian's Trilogy® and TrueBeam® systems to deliver these sophisticated treatments. "A large dose is given in one or just a few treatment sessions. Dose delivery is extremely accurate and precise, due to image-guidance, patient immobilization, and other technologies designed to ensure accuracy," he added.
Dr. Loo noted that studies conducted by researchers around the world have shown that SABR produces better tumor control rates, and higher overall survival rates, than conventional radiotherapy.(1)

To deliver SABR treatments at Stanford, Dr. Loo and his colleagues depend on the full spectrum of capabilities available to them with their Trilogy and TrueBeam systems, including fluoroscopic imaging for determining the extent of tumor motion, cone-beam CT imaging for pre-treatment patient positioning, respiratory gating for motion management, high dose delivery rates for efficiency, and RapidArc to attack the tumor from all angles in a 360-degree arc.

"SABR for early stage lung cancer is rapidly maturing, with promising early results," Dr. Loo concluded.

Another presentation, by Maria Chan, M.D., of Memorial Sloan Kettering Cancer Center, focused on the use of Varian's On-Board Imager® device to perform IGRT. The On-Board Imager is a standard component of Varian's high-energy linear accelerators for the treatment of cancer. It is used to generate radiographic (2-D), cone-beam CT (3-D) or fluoroscopic images that show how a tumor moves as a patient breathes in and out. These images make it possible to accurately pinpoint the tumor and adjust the patient's position just prior to each treatment.

More HCB News